JC virus-associated central nervous system diseases in HIV-infected patients in Brazil: Clinical presentations, associated factors with mortality and outcome  by Piza, Felipe et al.
1413-8670/© 2012 Elsevier Editora Ltda. 
www.elsevier.com/locate/bjid
The Brazilian Journal of
INFECTIOUS DISEASES
BRAZ J INFECT DIS. 2012;16(2):153-156
ArticLE info
Article history: 
received 28 August 2011 
Accepted 8 october 2011
Keywords:
Jc virus
Leukoencephalopathy, progressive 
multifocal
Diagnosis
Acquired immunodeficiency  
syndrome
Brazil
* Corresponding author at: rua cristiano Viana 279/53, São Paulo, SP, 05411-000, Brazil 
 E-mail address: josevibe@gmail.com (José E. Vidal)
A B S t r A c t
Introduction: Several presentations of neurologic complications caused by Jc virus (JcV) in 
human immunodeficiency virus (HiV)-infected patients have been described and need to 
be distinguished from the “classic” form of progressive multifocal leukoencephalopathy 
(PML). the objectives of this study were: 1) to describe the spectrum and frequency of 
presentations of JcV-associated central nervous system (cnS) diseases; 2) identify factors 
associated with in-hospital mortality of patients with JcV-associated cnS disease; and 
3) to estimate the overall mortality of this population. 
Material and methods: this was a retrospective study of HiV-infected patients admitted 
consecutively for JcV-associated cnS diseases in a referral teaching center in São Paulo, Brazil, 
from 2002 to 2007. All patients with laboratory confirmed JcV-associated cnS diseases were 
included using the following criteria: compatible clinical and radiological features associated with 
the presence of JcV DnA in the cerebrospinal fluid. JcV-associated cnS diseases were classified 
as follows: 1) classic PML; 2) inflammatory PML; and 3) Jc virus granule cell neuronopathy (Gcn). 
Results: We included 47 cases. JcV-associated cnS diseases were classified as follows: 
1) classic PML: 42 (89%); 2) inflammatory PML: three (6%); and 3) Jc virus Gcn: four (9%). 
nosocomial pneumonia (p = 0.003), previous diagnosis of HiV infection (p = 0.03), and 
imaging showing cerebellar and/or brainstem involvement (p = 0.02) were associated with 
in-hospital mortality. overall mortality during hospitalization was 34%.
Conclusions: novel presentations of JcV-associated cnS diseases were observed in our setting; 
nosocomial pneumonia, previous diagnosis of HiV infection, and cerebellar and/or brainstem 
involvement were associated with in-hospital mortality; and overall mortality was high. 
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Introduction
the incidence of progressive multifocal leukoencephalopathy 
(PML) has decreased in the highly active antiretroviral 
therapy (HAArt) era, although not to the same extent as 
that of other opportunistic infections of the central nervous 
system (cnS).1,2 in addition, PML appears to be far more 
common with acquired immunodeficiency syndrome (AiDS) 
than with other underlying immunosuppressive conditions.3
in Brazil, PML constitutes the fourth most frequent 
opportunistic complication after cerebral toxoplasmosis, 
cryptococcal meningoencephalitis, and cnS tuberculosis, the 
three more frequent neurological opportunistic infections 
in our setting.4,5 in recent years, novel presentations of 
JcV-associated cnS diseases have been described and need 
to be distinguished from the “classic” manifestations of PML. 
Scarce data are available about these other presentations and 
the clinical outcome of neurologic complications caused by 
JcV-associated cnS diseases in HiV-infected patients from 
Brazil. the objectives of this study were: 1) to describe the 
frequency of presentations of JcV-associated cnS diseases; 
2) to identify associated factors with in-hospital mortality of 
patients with JcV-associated cnS diseases; and 3) to estimate 
the overall mortality of this population.
Patients and methods
this is a retrospective study of HiV-infected patients admitted 
consecutively for JcV-associated cnS diseases at instituto de 
infectologia Emílio ribas, a referral teaching center in São 
Paulo, Brazil, between January 2002 and December 2007. 
All patients with laboratory-confirmed JcV infection were 
included using the following criteria: compatible clinical 
and radiological features (computerized tomography – ct 
– or magnetic resonance imaging – Mri) associated with 
the presence of JcV DnA in cSf.6-8 JcV-associated cnS 
diseases were classified at admission as follows: 1) classic 
PML; 2) PML-immune reconstitution inflammatory syndrome 
(iriS); and 3) JcV granule cell neuronopathy (Gcn). classic 
PML typically presents with subacute neurological deficits 
including hemiparesis or monoparesis, altered mental 
status, appendicular or gait ataxia, and visual symptoms.7 
inflammatory PML occurs in the setting of a recovery of 
the immune system marked by an increase in cD4+ cell 
count and a decrease in HiV plasma viral load.6-8 Patients 
with Gcn exclusively presented cerebellar syndrome and 
cerebellar atrophy in Mri without white matter lesions.7 
All patients received HAArt after JcV-associated cnS 
diseases diagnosis (de novo or intensification of treatment). 
Brainstem involvement was defined by the presence of 
clinical evidence of at least one of the following symptoms: 
oculomotor palsies, vestibular syndrome with dizziness, 
nausea, positional vomiting and nystagmus, swallowing 
disorders related to bulbar or pseudobulbar syndrome, stupor, 
and clouding of consciousness.9 Brainstem involvement was 
confirmed by the presence of brainstem demyelination on 
brain Mri. 
Univariate analysis was used to identify variables associated 
with death during hospitalization. A p-value ≤ 0.05 was 
considered significant. Patients with cerebellar and brainstem 
involvement were grouped into the same category. All patients 
included in this study were followed up until discharge or 
in-hospital death. Some of the survivors were followed in our 
outpatient care Unit. in order to estimate the proportion of 
survivors one year after the diagnosis of JcV-associated cnS 
diseases, a telephone call to patients without follow-up in our 
institution was performed. this study was approved by the 
institutional review Board of our center.
Results
We included 47 cases (median age: 37 years-old, male: 70%). 
42 patients (89%) had previous diagnosis of HiV infection. the 
median time from the beginning of the symptoms until the 
diagnosis was 39 days. Most frequent clinical manifestations 
were: speech disorder (64%), altered mental status (57%), focal 
weakness (49%), walking disturbances (43%), mental slowing 
(36%), cerebellar syndrome and/or brainstem involvement 
(36%), visual disturbances (24%), and seizures (19%). 
the median cD4+ cell count was 65 cells/mm3. the cD4+ 
cell count was categorized as follows: < 50 cells/mm3 = 26 
(55.3%), 51-100 cells/mm3 = eight (17%), 101-200 cells/mm3 = 10 
(21.3%), and > 200 cells/mm3: three (6.4%) cases. 
computerized tomography scans were performed in all 
cases and showed hypodense areas in the white matter in 91% 
(n = 42) of cases, and 71% (n = 30) of these cases presented 
multifocal lesions. cts with cerebellar and/or brainstem 
alterations were observed in 13 (29%) cases: hypodense 
areas in nine cases and cerebellar atrophy in five cases (one 
case simultaneously had hypodense areas in the cerebellar 
white matter and cerebellar atrophy). Mris were performed in 
these 13 cases: six had cerebellar white matter lesions, two had 
cerebellar and brainstem involvement, one had only brainstem 
alterations, and five cases showed cerebellar atrophy (one case 
simultaneously had cerebellar white matter and cerebellar 
athophy and four cases had isolated cerebellar atrophy). 
JcV-associated cnS diseases were classified upon admission as 
follows: 1) classic PML: 42 (89%); 2) PML-iriS: one (2%); 
and 3) JcV Gcn: four (9%). two patients with classic PML 
showed worsening of preexisting PML after the initiation of 
HAArt, in the context of a marked increase in cD4+ cell count 
and HiV plasma viral load below the limit of detection. thus, 
three (6%) of our patients had PML-iriS.
Among the 15 (32%) patients that had nosocomial 
pneumonia, 13 (87%) died. nosocomial pneumonia (p = 0.003), 
previous diagnosis of HiV infection (p  = 0.03), and ct imaging 
showing cerebellar and/or brainstem involvement (p = 0.02) were 
associated with in-hospital mortality. cD4+ cell count lower 
than 100 cells/mm3 showed a trend toward worse outcome 
(p = 0.06). overall mortality during hospitalization was 34% 
(n = 16). Among 11 patients with follow-up in our outpatient 
care Unit, eight (73%) patients were alive one year after the 
neurologic diagnosis. Among 20 patients without follow-up 
in our hospital after discharge, we obtained information on 
12 cases, and 10 (83%) of them were alive one year after the 
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neurologic diagnosis. Among patients with available data (n = 39, 
83%), overall mortality one year after the neurological diagnosis 
was 54% (n = 21). of these, 16 (76%) died during hospitalization.
Discussion
in this study, although infrequent, novel presentations of 
JcV-associated cnS diseases were observed; nosocomial 
pneumonia, previous diagnosis of HiV infection, and cerebellar 
and/or brainsteam involvement were associated with 
in-hospital mortality; and overall mortality was high. 
JcV-associated cnS diseases constitute a spectrum of diseases 
of which classic PML represent the most frequent and well 
described clinical presentation, as confirmed in the present study. 
in the HAArt era, PML-iriS happens in two settings. 
the first is when worsening of preexisting PML occurs after the 
initiation of HAArt (paradoxical iriS). the second setting is 
when PML and iriS develop simultaneously (unmasking iriS).10 
A recent study reported that approximately 33% and 67% of 
PML-iriS correspond to paradoxical and unmasking iriS, 
respectively.11 in contrast to reports from developed countries, 
where unmasking iriS accounts for up to 19% of PML cases,12,13 
we found only one (2%) case with this presentation. in addition, 
two (4%) other patients presented paradoxical iriS. the 
reasons for these lower frequencies are unknown. However, 
some potential variables include timing to start HAArt, JcV 
DnA levels in cSf, and/or JcV genotypes. 
Du Pasquier et al.14 have convincingly demonstrated 
productive JcV infection of cerebellar granule cell neurons in an 
HiV-infected patient. Afterward, a novel syndrome, distinct from 
PML, was called JcV granule cell neuronopathy.15 classically, 
patients with this presentation depict ataxia and cerebellar 
atrophy without white matter lesions in the cerebellum and 
show granule cell neurons  infected by a JcV variant.16 We 
and others have recently characterized JcV mutations in cSf 
of four JcV granule cell neuronopathy patients, including two 
from Brazil.17 in the present study, we found 9% of cases with 
probable JcV granule cell neuronopathy. nevertheless, a report 
found frequent infection of cerebellar granule cell neurons by 
JcV in PML and suggested that these cells may be the initial site 
of JcV infection in the cnS of HiV-infected patients.18
in previous studies, some variables were associated with 
worse prognosis among HiV-infected patients with PML, 
including diagnosis before the HAArt era, lower cD4+ cell 
counts, higher plasma HiV-1 rnA levels, lack of HiV clearance 
in plasma at month three, higher amounts of JcV DnA in 
cSf at the time of diagnosis, lack of JcV-specific cytotoxic 
t-lymphocytes, and brainstem involvement.7,8,10,12,19-22 in 
our exploratory analysis, we found that cerebellar and/or 
brainstem involvement and probably low cD4+ cell count 
were associated with in-hospital mortality. in accordance 
with these results, a recent study showed shorter survival 
time in AiDS-related PML patients with initial brainstem 
involvement, and 1-year probability of survival was 38% in 
patients with brainstem impairment versus 75% in patients 
without impairment.9 furthermore, lesions affecting 
the cerebellum tended to be more disabling, precluding 
independent living.23 
the level of immunossupression is an important risk 
factor for developing PML and dying due to this disease. A 
study found incidence rates of 0.2 and 9.1 cases per 1,000 
person-years at risk, respectively, for patients with cD4+ 
cell counts ≥ 200 versus < 200 cells/mm3.22 Another study 
estimated that 1-year survival was 48% in HiV-infected 
patients with cD4+ cell count < 200 cells/mm3 at PML 
diagnosis compared to 67% in those with cD4+ cell count 
> 200 cells/mm3.21
in addition, similar to other neurologic complications in 
our setting, nosocomial pneumonia was common among 
fatal cases.24 finally, we found a poorer outcome in patients 
with previous diagnosis of HiV infection. Probably this fact 
reflects non-adherence to HAArt or drug-resistant HiV. 
Prior studies identified a higher survival benefit in patients 
previously naïve to antiretrovirals who started HAArt at the 
time of PML diagnosis. Probably, in naive patients starting 
HAArt after neurological diagnosis, a rapid control of viral 
replication or the absence of HiV-resistant mutations may 
induce a more effective control of HiV replication, resulting 
in a more complete JcV-specific immune recovery.19 
in developed countries, the survival of patients with PML 
has increased substantially over the past 10 years, from 
0-30% one year after the diagnosis in the pre-HAArt era 
to 38-62% since its introduction.8,10,12,23 in addition, PML 
has a three month mortality rate of 20-50%.8 thus, the 
outcome of our patients was similar to that observed in 
developed countries, suggesting that the natural history 
of the disease can be modified in developing countries 
with access to HAArt, and that the prompt institution 
of HAArt is the most effective therapeutic approach in 
order to increase survival, at least in a subset of patients.24 
the overall mortality during hospitalization was high and 
could be justified, at least in part, due to the long time 
from the beginning of the symptoms until the diagnosis 
and subsequent antiretroviral treatment. Most patients 
included in this study were referred to our center after 
several evaluations in other services, usually of primary 
or secondary care and, in some instances, receiving 
unnecessary and prolonged empiric treatment (for example 
for cerebral toxoplasmosis). 
A recent nationwide cohort study performed in 
Denmark found that the median survival time among 
patients with PML diagnosed in the HAArt era was 1.8 
years.22 thus, despite the advances in recent years, the 
prognosis for patients with PML remains poor. this disease 
will continue to occur due to several reasons: patients 
fail to use HAArt (not under care or noncompliant with 
HAArt), HAArt failure due to resistance, and late HiV 
diagnosis (late presenters). in this setting, the main focus 
in the management of PML should be to avoid severe 
immunodepression in HiV-infected patients.22
in conclusion, PML constitutes the most frequent 
JcV-associated cnS disease in our setting, but novel 
presentations were observed. nosocomial pneumonia, 
previous diagnosis of HiV infection, and cerebellar and/or 
brainstem involvement were associated with in-hospital 
mortality. Despite increasing survival of patients with PML 
in the HAArt era, overall mortality continues to be high. 
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